Trial Profile

Immunotherapy Sequencing in COlon and REctal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Relatlimab (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Therapeutic Use
Acronyms iSCORE

Most Recent Events

13 Jun 2024 Planned End Date changed from 1 Dec 2023 to 1 Sep 2024.
07 May 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified May 2022).
01 Jul 2023 Results assessing vestigated whether RAS/BRAF wildtype MMRp mCRCs that had acquired resistanceto prior chemotherapy and an EGFR antibody benefi t from nivolumab (anti-PD1) andrelatlimab (anti-LAG3) ICIs presented at the 25th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com